PL2609075T3 - Sposób wytwarzania związków pośrednich do produkcji inhibitorów NEP - Google Patents

Sposób wytwarzania związków pośrednich do produkcji inhibitorów NEP

Info

Publication number
PL2609075T3
PL2609075T3 PL11758421.9T PL11758421T PL2609075T3 PL 2609075 T3 PL2609075 T3 PL 2609075T3 PL 11758421 T PL11758421 T PL 11758421T PL 2609075 T3 PL2609075 T3 PL 2609075T3
Authority
PL
Poland
Prior art keywords
intermediates
manufacture
preparation
nep inhibitors
nep
Prior art date
Application number
PL11758421.9T
Other languages
English (en)
Inventor
David Hook
Jianguang Zhou
Yunzhong Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2609075T3 publication Critical patent/PL2609075T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/12Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing organo-metallic compounds or metal hydrides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Materials Engineering (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL11758421.9T 2010-08-23 2011-08-22 Sposób wytwarzania związków pośrednich do produkcji inhibitorów NEP PL2609075T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2010076245 2010-08-23

Publications (1)

Publication Number Publication Date
PL2609075T3 true PL2609075T3 (pl) 2016-09-30

Family

ID=44658722

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11758421.9T PL2609075T3 (pl) 2010-08-23 2011-08-22 Sposób wytwarzania związków pośrednich do produkcji inhibitorów NEP

Country Status (14)

Country Link
US (1) US8835668B2 (pl)
EP (1) EP2609075B1 (pl)
JP (1) JP5705984B2 (pl)
KR (1) KR101476937B1 (pl)
AU (1) AU2011295170B2 (pl)
BR (1) BR112013004164A2 (pl)
CA (1) CA2806780A1 (pl)
ES (1) ES2576179T3 (pl)
MX (1) MX2013002150A (pl)
PL (1) PL2609075T3 (pl)
PT (1) PT2609075E (pl)
RU (1) RU2588572C2 (pl)
SI (1) SI2609075T1 (pl)
WO (1) WO2012025501A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091364A1 (es) 2008-01-17 2009-10-13 Novartis Ag Proceso para la preparacion de inhibidores de nep
PL3218351T3 (pl) 2014-11-14 2019-12-31 Zentiva K.S. Sposób wytwarzania, wyodrębniania i oczyszczania farmaceutycznie dopuszczalnych postaci AHU-377
TW201632493A (zh) 2015-02-13 2016-09-16 諾華公司 新穎方法
WO2016135751A1 (en) 2015-02-25 2016-09-01 Mylan Laboratories Limited Novel process for the preparation of sacubitril and its intermediates
WO2017051326A1 (en) 2015-09-23 2017-03-30 Novartis Ag New processes and intermediates useful in synthesis of nep inhibitors
US10377697B2 (en) 2015-12-10 2019-08-13 Novartis Ag Process and intermediates
WO2017097275A1 (en) 2015-12-11 2017-06-15 Zentiva, K.S. Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method
WO2018007919A1 (en) 2016-07-05 2018-01-11 Novartis Ag New process for early sacubitril intermediates
EP3500549B1 (en) 2016-08-17 2020-12-16 Novartis AG New processes and intermediates for nep inhibitor synthesis
CN110088079A (zh) 2016-12-23 2019-08-02 诺华股份有限公司 用于早期沙卡布曲中间体的新方法
CN106946742A (zh) * 2017-03-28 2017-07-14 常州沃腾化工科技有限公司 一种三苯基氧磷含量低的沙库必曲中间体的制备方法
CN109503404A (zh) * 2018-12-28 2019-03-22 凯瑞斯德生化(苏州)有限公司 一种lcz-696关键中间体的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5015793B2 (pl) 1972-06-07 1975-06-07
JPS53103412A (en) * 1977-02-18 1978-09-08 Kuraray Co Ltd Preparation of farnesyl acetic acid or its ester
US4219683A (en) * 1978-09-25 1980-08-26 Phillips Petroleum Company Isomerization of unsaturated alcohols
FR2597100A1 (fr) 1986-01-21 1987-10-16 Nippon Shinyaku Co Ltd Derives du pyroglutamide
DE3713127A1 (de) * 1987-04-16 1988-11-03 Consortium Elektrochem Ind Verfahren zur herstellung von tiglinaldehyd
JPH07103101B2 (ja) 1989-07-24 1995-11-08 キッセイ薬品工業株式会社 ピログルタミン酸誘導体
PH30484A (en) 1990-02-19 1997-05-28 Ciba Geigy Acy compounds pharmaceutical composition containing said compound and method of use thereof
US5250522A (en) 1992-10-09 1993-10-05 Ciba-Geigy Corporation Phosphono/biaryl substituted amino acid derivatives
US5273990A (en) 1992-09-03 1993-12-28 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives
FR2688503B1 (fr) 1992-03-16 1994-05-06 Synthelabo Procede de preparation de derives de 2-(tetrazol-5-yl)-[1,1'-biphenyle].
EP0550313A1 (fr) 1991-12-30 1993-07-07 Synthelabo Nouveaux dérivés de 2-(tétrazol-5-yl)-(1,1'-biphényle), leur préparation et leur utilisation comme intermédiaires de synthèse
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US5412102A (en) 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
US5550119A (en) 1995-03-02 1996-08-27 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives as ECE inhibitors
KR19990082639A (ko) 1996-02-19 1999-11-25 미즈노 마사루 당뇨병 치료제
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6207825B1 (en) 1997-11-14 2001-03-27 Mitsui Chemicals, Inc. Method for production of pyrrolidinone derivatives
CA2344412A1 (en) 1998-09-21 2000-03-30 Takeda Chemical Industries, Ltd. Thiol compound, their production and use
MXPA02008931A (es) * 2000-03-16 2003-02-10 Hoffmann La Roche Derivados de acido carboxilico como antagonistas ip.
EP1467728B1 (en) 2002-01-17 2007-08-22 Novartis AG Pharmaceutical compositions comprising valsartan and nep inhibitors
AU2003236180A1 (en) 2002-03-29 2003-10-13 Senju Pharmaceutical Co., Ltd. Hydroxymorpholinone derivative and medicinal use thereof
GB0402262D0 (en) 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
EP1756131B1 (en) 2004-05-07 2007-11-28 Umicore AG & Co. KG Ferrocenyl ligands for homogeneous, enantioselective hydrogenation catalysts
GB0418046D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
MY146830A (en) 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
EP1903027A1 (en) 2006-09-13 2008-03-26 Novartis AG Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors
BRPI0806700A8 (pt) 2007-01-12 2019-01-22 Novartis Ag processo
EP2532673A3 (en) 2007-05-10 2014-01-08 R & D Biopharmaceuticals Gmbh Tubulysine derivatives
PE20091364A1 (es) * 2008-01-17 2009-10-13 Novartis Ag Proceso para la preparacion de inhibidores de nep
CN102712585B (zh) 2010-01-22 2015-06-24 诺华股份有限公司 中性内肽酶抑制剂中间体和其制备方法
ES2608780T3 (es) 2010-08-23 2017-04-17 Novartis Ag Nuevo proceso para la preparación de intermediarios útiles para la elaboración de inhibidores de NEP

Also Published As

Publication number Publication date
AU2011295170A1 (en) 2013-03-21
BR112013004164A2 (pt) 2016-05-10
AU2011295170B2 (en) 2014-12-18
ES2576179T3 (es) 2016-07-06
EP2609075B1 (en) 2016-03-16
RU2013112946A (ru) 2014-09-27
US8835668B2 (en) 2014-09-16
KR101476937B1 (ko) 2014-12-24
EP2609075A1 (en) 2013-07-03
RU2588572C2 (ru) 2016-07-10
JP2013539462A (ja) 2013-10-24
WO2012025501A1 (en) 2012-03-01
KR20130061735A (ko) 2013-06-11
MX2013002150A (es) 2013-04-03
CA2806780A1 (en) 2012-03-01
JP5705984B2 (ja) 2015-04-22
SI2609075T1 (sl) 2016-06-30
US20130158285A1 (en) 2013-06-20
PT2609075E (pt) 2016-06-03

Similar Documents

Publication Publication Date Title
PL2609071T3 (pl) Nowy sposób otrzymywania związków pośrednich użytecznych do wytwarzania inhibitorów NEP
PL2609075T3 (pl) Sposób wytwarzania związków pośrednich do produkcji inhibitorów NEP
EP2609120A4 (en) IMPROVED PROCESS FOR PREPARING SUGAMMADEX
IL246265B (en) A method for the production of intermediates for the preparation of 5-fluoro-h1-pyrazolopyridines and such compounds
EP2552874A4 (en) PROCESS FOR PREPARING HEXAFLUOR-2 BUTENE
ZA201308446B (en) Process for the production of estetrol intermediates
EP2558432A4 (en) METHOD FOR THE PRODUCTION OF TETRAFLUOROLEFINES
ZA201308445B (en) Process for the production of estetrol intermediates
ZA201308852B (en) Process of making beta-hydroxyamino compounds
SG11201400939YA (en) Process for the preparation of methoxymelonal
IL232424A (en) Process for the preparation of 1-noble-4-phenylsulfonylprolinamide and intermediates
HUE044066T2 (hu) Eljárás metilén-difenil-diizocianát elõállítására
EP2596007A4 (en) PROCESS FOR THE PREPARATION OF 17-DEOXY-CORTICOSTEROIDS
ZA201300546B (en) Process for the preparation of 3-haloalkylpyrazoles
TWI562985B (en) Process for the preparation of enolate salts of 4-fluoro-2-hydroxymethylene-3-oxobutyrates
PT2603319E (pt) Processo para a preparação de uretanos
GB201119690D0 (en) Process for the preparation of compounds
PT2390246T (pt) Processo para a preparação de aminaftona
EP2537851A4 (en) PROCESS FOR PREPARING B-GLYCOSIDE COMPOUNDS
PL393916A1 (pl) Sposób wytwarzania związków karbapenamowych
PL2598504T3 (pl) Sposób otrzymywania dimiracetamu
PT2673282T (pt) Processo inovador para a preparação de ácidos drónicos
IL224304A (en) A process for making dichlorobulben
PL394378A1 (pl) Sposób otrzymywania E-2-amino-4-nitrostilbenów
PL394420A1 (pl) Sposób wytwarzania dilauroilofluoresceiny